16 Apr, 2021 05:46 PM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Gover...read more
14 Apr, 2021 09:25 AM
The last few months have certainly been a very busy period, not only for Immutep but for our whole sector. I would like to take the opportunity in our newsletter to add a bit more colour to the sign...read more
08 Apr, 2021 07:52 AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and aut...read more
07 Apr, 2021 08:28 AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and aut...read more
16 Mar, 2021 08:17 AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and aut...read more
12 Mar, 2021 05:02 PM
S&P Dow Jones Indices announced today the changes in the S&P/ASX Indices, effective prior to the open of trading on March 22, 2021, as a result of the March quarterly review.
For more inf...read more
09 Mar, 2021 04:14 PM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and auto-...read more
05 Mar, 2021 08:21 AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of...read more
25 Feb, 2021 08:24 AM
IVE Group Limited (IVE Group or The Company, ASX:IGL) is pleased to announce its results for the six months ended 31 December 2020 (1H FY21).
The strength of IVE's client relationships, flexi...read more
